Nintedanib Alternatives Compared
| Nintedanib | Ofev | Esbriet |
|
|---|
| Nintedanib | Ofev (nintedanib) | Esbriet (pirfenidone) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Idiopathic Pulmonary Fibrosis, Chronic Fibrosing Interstitial Lung Disease With A Progressive Phenotype, Systemic Sclerosis-Associated Interstitial Lung Disease. Nintedanib may also be... View more |
Prescription only
Prescribed for Idiopathic Pulmonary Fibrosis, Chronic Fibrosing Interstitial Lung Disease With A Progressive Phenotype, Systemic Sclerosis-Associated Interstitial Lung Disease. Ofev may also be used... View more |
Prescription only
Prescribed for Idiopathic Pulmonary Fibrosis. Esbriet may also be used for purposes not listed in this medication guide. |
Related suggestions Idiopathic Pulmonary Fibrosis
|
|||||||||||||||
| More about Nintedanib | More about Ofev (nintedanib) | More about Esbriet (pirfenidone) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Nintedanib has an average rating of 7.9 out of 10 from a total of 31 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 4% reported a negative effect. |
Ofev has an average rating of 7.9 out of 10 from a total of 23 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 5% reported a negative effect. |
Esbriet has an average rating of 7.7 out of 10 from a total of 11 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 10% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ofev prices |
View all Esbriet prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Ofev |
N/A |
N/A |
||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
9.5 hours |
9.5 hours |
3 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 247 drugs are known to interact with Nintedanib:
|
A total of 247 drugs are known to interact with Ofev:
|
A total of 152 drugs are known to interact with Esbriet:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
October 15, 2014 |
October 15, 2014 |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.